Popov V V, Menenkova E Yu, Babakhina S N, Bezzubik E G, Isakova Yu A, Lezina D S, Dmukhovski D V, Merkulov Yu A, Merkulova D M
Semashko Research Clinical Center of the 'Russian Railways', Moscow; Sechenov First Moscow State Medical University, Moscow.
Semashko Research Clinical Center of the 'Russian Railways', Moscow.
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(12):118-122. doi: 10.17116/jnevro2015115112118-122.
To evaluate clinical efficacy and tolerability of electrode pharmaphoresis using preparations xefocam and mydocalm-richter in railway workers with low-back pain.
Authors carried out an open prospective noncomparative study of 16 patients, aged 21-82 years, with spinal osteochondrosis with root syndrome and radiculopathia of the lumbar/sacral spine with pain syndrome regardless of its duration. Treatment efficacy was assessed by the dynamics of pain syndrome severity based on the scores of a self-rated scale completed by the patient and the McGill Pain Questionnaire. Quality-of-life was assessed with the Oswestry Disability Index before and in the end of treatment. Clinical outcome was evaluated with the modified Nurick scale. Electrode pharmaphoresis (the "Farma T.E.B. Trans Epidermal Barrier Physio" apparatus) was administered to all patients using xefocam (solution for injections 8 mg, 2 ml per procedure) and mydocalm-richter (solution for injections 100 mg, 2 ml per injection) in the lumbar/sacral spine.
The high clinical efficacy of electrode pharmaphoresis using xefocam and mydocalm-richter was shown. The complex restoration study resulted in the reduction of pain syndrome in all patients. Pain severity was reduced to mild grade in 68.8% to the middle of treatment and in 93.8% patients in the end of treatment. As a consequence of pain reduction, the functional activity (quality of self-service, daily activities) increased significantly in 68.8% of patients. Positive treatment effect was noted in 100% of patients, good tolerability of this medication in 87.5%.
评估使用凯纷和利筋诺制剂的电极导入疗法对患有腰痛的铁路工人的临床疗效和耐受性。
作者对16例年龄在21 - 82岁之间、患有脊柱骨软骨病伴根性综合征以及腰骶部脊柱神经根病且伴有疼痛综合征（疼痛持续时间不限）的患者进行了一项开放性前瞻性非对照研究。根据患者完成的自评量表评分和麦吉尔疼痛问卷评估疼痛综合征严重程度的动态变化来评估治疗效果。在治疗前和治疗结束时用奥斯维斯特残疾指数评估生活质量。用改良的努里克量表评估临床结果。使用“Farma T.E.B. Trans Epidermal Barrier Physio”仪器对所有患者在腰骶部脊柱进行电极导入疗法，使用凯纷（注射用溶液8毫克，每次治疗2毫升）和利筋诺（注射用溶液100毫克，每次注射2毫升）。
结果显示使用凯纷和利筋诺的电极导入疗法具有较高的临床疗效。综合恢复研究使所有患者的疼痛综合征减轻。到治疗中期，68.8%的患者疼痛严重程度降至轻度，治疗结束时93.8%的患者疼痛严重程度降至轻度。由于疼痛减轻，68.8%的患者功能活动（自理、日常活动质量）显著增加。100%的患者有积极的治疗效果，87.5%的患者对该药物耐受性良好。
